BioXcel Therapeutics (BTAI) Insider Trading & Ownership $0.34 +0.03 (+8.12%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BioXcel Therapeutics (NASDAQ:BTAI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage28.70%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$236,298.04 Get BTAI Insider Trade Alerts Want to know when executives and insiders are buying or selling BioXcel Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BTAI Insider Buying and Selling by Quarter Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. BioXcel Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/16/2024Richard I SteinhartCFOSell577$0.36$207.72 12/16/2024Vimal MehtaCEOSell3,117$0.36$1,122.12 12/16/2024Vincent O'neillInsiderSell165$0.35$57.75 10/3/2024Matthew T WileyInsiderSell6,272$0.55$3,449.60 10/3/2024Richard I SteinhartCFOSell7,175$0.55$3,946.25 9/16/2024Frank YoccaInsiderSell355$0.69$244.95 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/16/2024Richard I SteinhartCFOSell356$0.69$245.64 9/16/2024Vimal MehtaCEOSell1,982$0.69$1,367.58 6/17/2024Frank YoccaInsiderSell372$1.28$476.16 6/17/2024Vimal MehtaCEOSell2,134$1.28$2,731.52 6/4/2024Vimal MehtaCEOSell126,014$1.63$205,402.82 4/4/2024Richard I SteinhartCFOSell1,069$2.63$2,811.47 4/4/2024Vimal MehtaCEOSell5,268$2.62$13,802.16 4/4/2024Vincent O'neillInsiderSell165$2.62$432.30 (Data available from 1/1/2013 forward) BTAI Insider Trading Activity - Frequently Asked Questions Who is on BioXcel Therapeutics's Insider Roster? The list of insiders at BioXcel Therapeutics includes Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Matthew T Wiley, Richard I Steinhart, Vimal Mehta, and Vincent O'neill. Learn more on insiders at BTAI. What percentage of BioXcel Therapeutics stock is owned by insiders? 28.70% of BioXcel Therapeutics stock is owned by insiders. Learn more on BTAI's insider holdings. Which BioXcel Therapeutics insiders have been selling company stock? The following insiders have sold BTAI shares in the last 24 months: Frank Yocca ($1,520,115.76), Javier Rodriguez ($48,766.20), Krishnan Nandabalan ($1,617,560.26), Matthew T Wiley ($3,449.60), Richard I Steinhart ($183,699.08), Vimal Mehta ($1,670,301.20), and Vincent O'neill ($490.05). How much insider selling is happening at BioXcel Therapeutics? Insiders have sold a total of 371,764 BioXcel Therapeutics shares in the last 24 months for a total of $5,044,382.15 sold. BioXcel Therapeutics Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, President, & Director Compensation: $1.76MMr. Javier Rodriguez (Age 51)Senior VP, Chief Legal Officer & Corporate Secretary Compensation: $638.88kMr. Matthew Wiley (Age 51)Senior VP & Chief Commercial Officer Compensation: $620.12k1 recent tradesMr. Richard I. Steinhart MBA (Age 67)Senior VP & CFO Compensation: $404k3 recent tradesDr. Frank D. Yocca Ph.D. (Age 67)Senior VP & Chief Scientific Officer Compensation: $452.58kDr. Vincent J. O'Neill B.Sc. (Age 55)M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer Compensation: $510.17kDr. Chetan D. Lathia Ph.D.Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - Neuroscience More Insider Trading Tools from MarketBeat Related Companies Spero Therapeutics Insider Selling Aadi Bioscience Insider Selling Mural Oncology Insider Selling Invivyd Insider Selling Kronos Bio Insider Selling Immix Biopharma Insider Selling Immuneering Insider Selling Janone Insider Selling Shattuck Labs Insider Selling AlloVir Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:BTAI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.